VHL and cancer: Responsiveness of RCCs such as VHL-positive Caki-2 cells for conventional anticancer agents such as camptothecin (CPT), etoposide (VP-16) and doxorubicin (DOX) was lower than that of other types of cancer such as Hela cells [4], [5], [6], [7], [8], [9].